Absci (ABSI) Share-based Compensation (2020 - 2026)
Absci (ABSI) reported Share-based Compensation of $4.4 million for Q1 2026, down 10.85% on a YoY basis from $4.9 million in Q1 2025, and up 2.89% sequentially from $4.3 million in Q4 2025.
Absci (ABSI) Share-based Compensation (2020 - 2026) Analysis & Trends
Absci (ABSI) has 7 years of Share-based Compensation data on file, last reported at $4.4 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 10.85% year-over-year to $4.4 million; the trailing twelve-month figure through Mar 2026 stood at $17.8 million (down 14.38% YoY), and the FY2025 full-year result was $18.3 million, down 5.81% from the prior year.
- Share-based Compensation rose to $4.4 million in Q1 2026, from $4.3 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $19.0 million in Q4 2024 to a low of -$11.4 million in Q4 2022.
- A 5-year average of $3.4 million and a median of $4.2 million in 2022 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 1500.38% in 2022, while the deepest fall reached 452.88% in 2022.
- Tracing ABSI's Share-based Compensation over 5 years: stood at -$11.4 million in 2022, then surged by 200.1% to $11.4 million in 2023, then soared by 66.6% to $19.0 million in 2024, then sank by 77.62% to $4.3 million in 2025, then climbed by 2.89% to $4.4 million in 2026.
- Business Quant data shows ABSI's Share-based Compensation at $4.4 million in Q1 2026, $4.3 million in Q4 2025, and $4.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Absci | 1.23 Bn | 1.11 Bn | - | 4.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.38 Mn |
| Mar 31, 2026 | 4.38 Mn |
| Dec 31, 2025 | 4.26 Mn |
| Dec 31, 2025 | 4.26 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Mar 31, 2025 | 4.91 Mn |
| Mar 31, 2025 | 4.91 Mn |
| Dec 31, 2024 | 19.02 Mn |
| Dec 31, 2024 | 19.02 Mn |
| Sep 30, 2024 | -8.45 Mn |
| Sep 30, 2024 | -8.45 Mn |
| Jun 30, 2024 | 5.29 Mn |
| Jun 30, 2024 | 5.29 Mn |
| Mar 31, 2024 | 3.59 Mn |
| Mar 31, 2024 | 3.59 Mn |
| Dec 31, 2023 | 11.42 Mn |
| Dec 31, 2023 | 11.42 Mn |